stem cells-the next boom, page-8

The other interesting factor to consider is that the caps of other companies are all partnered with a major.

So you have a stage 1 company in upcoming clinical trials in a very hot sector with new and innovative technology.

In the next 9 months I am expecting partnerships and funding (50/50 with a major).

We may even have multiple trails occuring.

Significant rerate ahead on the material change in company since Cynata development here. Clinical data supports this theory going into trials.